Hepatitis b drug study halted before it began
NCT ID NCT02349126
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 27 times
Summary
This study planned to test a new drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower a key virus marker (HBsAg) more effectively. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.